Evolus (NASDAQ: EOLS) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Evolus to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current ratings and price targets for Evolus and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus 0 0 4 0 3.00
Evolus Competitors 1355 3812 12552 279 2.65

Evolus currently has a consensus price target of $22.50, suggesting a potential upside of 87.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.38%. Given Evolus’ stronger consensus rating and higher probable upside, equities analysts plainly believe Evolus is more favorable than its peers.

Profitability

This table compares Evolus and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolus N/A N/A N/A
Evolus Competitors -6,244.01% -164.20% -35.98%

Earnings and Valuation

This table compares Evolus and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evolus N/A -$20.06 million -22.17
Evolus Competitors $267.94 million -$30.77 million -34.07

Evolus’ peers have higher revenue, but lower earnings than Evolus. Evolus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

52.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Evolus beats its peers on 8 of the 12 factors compared.

About Evolus

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.